Auro Laboratories (BSE:530233) - Aandelenkoers, Nieuws & Analyse

530233 Overzicht aandelen

Auro Laboratories Limited produceert en verkoopt actieve farmaceutische ingrediënten (API's), tussenproducten en generieke formuleringen in India.

Over het bedrijf

530233 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

Price-To-Earnings ratio (19.6x) is below the Indian market (33.3x)

Earnings grew by 155.5% over the past year

Risicoanalyse

Does not have a meaningful market cap (₹2B)

Has a high level of debt

Auro Laboratories Limited Concurrenten

Sotac Pharmaceuticals

NSEI:SOTAC

₹1.3b

Source Natural Foods and Herbal Supplements

BSE:531398

₹1.5b

Tyche Industries

BSE:532384

₹1.9b

BDH Industries

BSE:524828

₹1.8b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Auro Laboratories
Historische aandelenkoersen
Huidige aandelenkoers	₹246.25
52 Week Hoogtepunt	₹307.20
52 Week Laag	₹108.10
Bèta	0.53
11 maand verandering	10.75%
3 maanden verandering	54.53%
1 Jaar Verandering	123.76%
33 jaar verandering	103.85%
5 jaar verandering	342.90%
Verandering sinds IPO	11,853.88%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	530233	IN Pharmaceuticals	IN Markt
7D	8.3%	2.0%	1.8%
1Y	123.8%	58.6%	36.8%

Rendement versus industrie: 530233 exceeded the Indian Pharmaceuticals industry which returned 58.6% over the past year.

Rendement versus markt: 530233 exceeded the Indian Market which returned 36.8% over the past year.

Prijsvolatiliteit

Is 530233's price volatile compared to industry and market?
530233 volatility
530233 Average Weekly Movement	6.9%
Pharmaceuticals Industry Average Movement	6.3%
Market Average Movement	6.3%
10% most volatile stocks in IN Market	9.4%
10% least volatile stocks in IN Market	4.0%

Stabiele aandelenkoers: 530233 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatiliteit in de loop van de tijd: 530233's weekly volatility (7%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1989	n/a	Sharat Deorah	www.aurolabs.com

Auro Laboratories Limited produceert en verkoopt actieve farmaceutische ingrediënten (API's), tussenproducten en generieke formuleringen in India. Het biedt API's voor verschillende geneesmiddelen, zoals antihistamine, spierverslappers, diuretica, ijzergebrek, antidiabetica, antischimmelmiddelen, middelen tegen zweren, jodiumsupplementen, middelen tegen malaria, pijnstillers, maagzuurremmers en ontstekingsremmers, evenals voor andere producten, waaronder kaliumjodide, natriumjodide en microkristallijne cellulose. Het bedrijf levert ook speciale chemicaliën bestaande uit guanidine nitraat, dimethyl amine HCl, 2-ethoxy benzoëzuur en 3,4,5 - trimethoxy benzoëzuur.

Auro Laboratories Limited Samenvatting

Hoe verhouden de winst en inkomsten van Auro Laboratories zich tot de beurswaarde?
530233 fundamentele statistieken
Marktkapitalisatie	₹1.58b
Inkomsten(TTM)	₹78.37m
Inkomsten(TTM)	₹491.73m

19.6x

Koers/Winstverhouding

3.1x

P/S-verhouding

Is 530233 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
530233 resultatenrekening (TTM)
Inkomsten	₹491.73m
Kosten van inkomsten	₹227.27m
Brutowinst	₹264.46m
Overige uitgaven	₹186.09m
Inkomsten	₹78.37m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	12.57
Brutomarge	53.78%
Nettowinstmarge	15.94%
Schuld/Eigen Vermogen Verhouding	62.5%

Hoe presteerde 530233 op de lange termijn?

Bekijk historische prestaties en vergelijking

530233 Overzicht aandelen

Beloningen

Risicoanalyse

Auro Laboratories Limited Concurrenten

NSEI:SOTAC

₹1.3b

BSE:531398

₹1.5b

BSE:532384

₹1.9b

BSE:524828

₹1.8b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Investor sentiment improves as stock rises 19%

First quarter 2025 earnings released: EPS: ₹1.21 (vs ₹1.14 in 1Q 2024)

Auro Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Auro Laboratories Limited Announces Resignation of Sweta Agarwal as Company Secretary and Compliance Officer, Effective July 30, 2024

Investor sentiment deteriorates as stock falls 17%

Full year 2024 earnings released: EPS: ₹12.50 (vs ₹3.92 in FY 2023)

Recent updates

Investor sentiment improves as stock rises 19%

First quarter 2025 earnings released: EPS: ₹1.21 (vs ₹1.14 in 1Q 2024)

Auro Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Auro Laboratories Limited Announces Resignation of Sweta Agarwal as Company Secretary and Compliance Officer, Effective July 30, 2024

Investor sentiment deteriorates as stock falls 17%

Full year 2024 earnings released: EPS: ₹12.50 (vs ₹3.92 in FY 2023)

Auro Laboratories Limited to Report Q4, 2024 Results on May 25, 2024

Investor sentiment improves as stock rises 26%

Less than half of directors are independent

Investor sentiment improves as stock rises 15%

Third quarter 2024 earnings released: EPS: ₹4.39 (vs ₹0.59 in 3Q 2023)

Auro Laboratories Limited to Report Q3, 2024 Results on Feb 06, 2024

Investor sentiment improves as stock rises 21%

Auro Laboratories Limited Appoints Shaan Jain as Chief Financial Officer

Investor sentiment improves as stock rises 23%

Second quarter 2024 earnings released: EPS: ₹3.16 (vs ₹0.34 in 2Q 2023)

Auro Laboratories Limited to Report Q2, 2024 Results on Nov 09, 2023

Auro Laboratories Limited Announces the Resignation of Amit Mahipat Shah as Chief Financial Officer, Effective October 1, 2023

Auro Laboratories Limited Appoints Vishal Kailashchandra Jhunjhunwala as an Non-Executive & Independent Director

Less than half of directors are independent

Auro Laboratories Limited, Annual General Meeting, Sep 23, 2023

Auro Laboratories Limited Announces Resignation of Govardhan Das Agarwal as Director

First quarter 2024 earnings released: EPS: ₹1.14 (vs ₹0.13 in 1Q 2023)

Auro Laboratories Limited to Report Q1, 2024 Results on Jul 31, 2023

Full year 2023 earnings released: EPS: ₹3.92 (vs ₹4.56 in FY 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings released: EPS: ₹0.59 (vs ₹0.98 in 3Q 2022)

Auro Laboratories Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: EPS: ₹0.34 (vs ₹1.14 in 2Q 2022)

Auro Laboratories Limited to Report Q2, 2023 Results on Nov 14, 2022

First quarter 2023 earnings released: EPS: ₹0.13 (vs ₹1.71 in 1Q 2022)

Auro Laboratories Limited to Report Q1, 2023 Results on Aug 02, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹11.52 in FY 2021)

Auro Laboratories Limited Announces Management Changes

Auro Laboratories Limited to Report Q4, 2022 Results on May 30, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Whole Time Director recently bought ₹86k worth of stock

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS ₹1.71 (vs ₹2.22 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS ₹11.52 (vs ₹6.51 in FY 2020)

Investor sentiment improved over the past week

Auro Laboratories Limited Appoints Mrs. Kavita Sharma as Independent Director

Auro Laboratories Limited to Report Q3, 2021 Results on Feb 11, 2021

Investor sentiment improved over the past week

New 90-day high: ₹98.80

Second quarter 2021 earnings released: EPS ₹3.62

Market bids up stock over the past week

Auro Laboratories Limited to Report Q2, 2020 Results on Nov 05, 2020

New 90-day high: ₹67.65

New 90-day high - ₹58.10

First quarter earnings released

Auro Laboratories Limited to Report Q1, 2021 Results on Aug 31, 2020

New 90-day high - ₹52.25

Rendement voor aandeelhouders

Prijsvolatiliteit